Eva Venegas‐Moreno

Hospital Universitario Virgen del Rocío — Spain

Medicine · Health Sciences

18h-index1.0kcitations86works0.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pituitary Gland Disorders and Treatments(75), Neuroendocrine Tumor Research Advances(24), Growth Hormone and Insulin-like Growth Factors(22), Adrenal and Paraganglionic Tumors(11), Glioma Diagnosis and Treatment(5)

Publications86 total

Efficacy and safety of sepiapterin versus sapropterin in patients with phenylketonuria: Results from the Phase 3, randomized, crossover, open-label, active-controlled AMPLIPHY trial
Metabolism·2026Open Access
UCO-IMIBIC Consensus for the Definition of Competencies Related to Human Clinical Research in Higher Education Life Sciences Degree Programs (Preprint)
2025Open Access
Impaired splicing machinery in craniopharyngiomas unveils PRPF8 and RAVER1 as novel biomarkers and therapeutic targets
Acta Neuropathologica Communications·2025Open Access
Impact of Flash Glucose Monitoring in Adults with Inherited Metabolic Disorders at Risk of Hypoglycemia
Nutrients·2025Open Access
Conditional Pten inactivation in pituitary results in sex-specific prolactinoma formation
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease·2024· 1 cited
Metabolic and surgical outcomes of adult patients with craniopharyngiomapatients undergoing extended transsphenoidal surgery (ETS) at a referral center
Endocrine Abstracts·2023
Figure S5 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S3 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S7 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S8 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S3 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S7 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S2 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S8 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S5 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S4 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S6 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S1 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Data from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Supplementary Data from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Alfonso Soto‐Moreno(46), Raúl M. Luque(30), Justo P. Castaño(29), David A. Cano(24), Alejandro Ibáñez‐Costa(23), Manuel D. Gahete(20), Mari C. Vázquez‐Borrego(20), María A. Gálvez(18), Ainara Madrazo‐Atutxa(14), Miguel Á. Japón(14), Michael D. Culler(12), Elena de Dios(12), Cristóbal Blanco-Acevedo(12), Alfonso Leal‐Cerro(11), Pablo Remón-Ruiz(11), Ana Barrera-Martín(10), María Ángeles Gálvez-Moreno(10), Juan Solivera(9), Juan Francisco Martin‐Rodríguez(8), Elena Torres‐Vela(7)